Scientific Zambon Pharma February 20, 2020 Breath Therapeutics, a Zambon company, initiates BOSTON-3 and BOSTON-4, two additional clinical studies for the treatment of bronchiolitis obliterans syndrome (BOS)
Scientific Zambon Pharma November 13, 2019 Zambon entered in an exclusive license agreement to register and commercialize riluzole Oral Film in Europe for ALS
Scientific Zambon Pharma October 16, 2019 Breath Therapeutics, a Zambon company, announces presentations at upcoming scientific conferences
Institutional Zambon Pharma July 25, 2019 Zambon completes transformational acquisition of Breath Therapeutics
Scientific Zambon Pharma July 11, 2019 Valeo Pharma Announces the Canadian Launch of Onstryv® (Safinamide Tablets) for the Treatment of Parkinson’s Disease
Scientific Zambon Pharma January 15, 2019 Valeo Pharma and Zambon announce the approval of Onstryv® (safinamide) for Canada